Microneedling, also called collagen induction therapy, is a minimally invasive procedure that creates controlled microchannels in the skin to stimulate wound-healing pathways. The peer-reviewed evidence in 2024 and 2025 supports its use for acne scars, post-inflammatory hyperpigmentation, and select dermatologic conditions. Older reviews flagged anecdotal recommendations; the newer systematic literature is more confident, with caveats. UK practitioners working with the technique need to understand both what the evidence supports and what the documentation standard now looks like, as the regulatory environment around devices and procedures continues to develop.
What microneedling is, in clinical terms
Microneedling devices use fine needles, typically 0.25 mm to 2.5 mm in length, to create controlled micro-injuries in the dermis. The injuries trigger a wound-healing cascade involving fibroblast activity, collagen and elastin synthesis, and epidermal turnover. The treatment is delivered with manual rollers, motorised pens, or radiofrequency-assisted devices that combine the needling with thermal energy.
The comprehensive 2024 review in Cureus groups the technique into three categories: manual, motorised, and RF-assisted. Depth and frequency are the variables most consistently associated with outcomes in the literature. The device category also determines the regulatory classification of the equipment in use, which matters for compliance and documentation.
The evidence shift through 2024 and 2025
The older microneedling literature read cautiously. A 2017 review in the Indian Dermatology Online Journal described the evidence base as predominantly anecdotal, with most recommendations grounded in small studies and clinical experience rather than controlled trials.
The picture has changed. The 2024 Cureus review and a 2025 systematic review of microneedling for non-cosmetic dermatologic conditions both report that the evidence has matured. Across pooled studies, microneedling now shows consistent efficacy for acne scarring, hyperpigmentation, alopecia (when combined with topical minoxidil or PRP), and stretch marks.
What changed: better-designed RCTs, larger sample sizes, and clearer reporting of needle depth, session count, and adjunct use. The literature is no longer a collection of case series. It is a body of work with reproducible outcomes for specific indications.
Indications with the strongest support
Across the recent systematic literature, the indications with the most consistent published support are:
- Atrophic acne scarring, particularly icepick and rolling scars, with multiple RCTs reporting clinically significant improvement. For practitioners building a clinical framework around acne sequelae, Free Acne Decoded covers the assessment and treatment approach in the first three lessons at no cost.
- Post-inflammatory hyperpigmentation, improvement in melanin index across pooled studies, with particularly strong outcomes when paired with topical depigmenting agents. Hyperpigmentation Decoded, The Mini is the free three-lesson introduction to the pigmentation management framework.
- Striae (stretch marks), improvement in texture and elasticity for both striae rubra and striae albae.
- Androgenetic alopecia, efficacy demonstrated when combined with topical minoxidil or platelet-rich plasma, with meta-analytic support published in 2024.
- Photoageing and fine lines, improvement in skin texture and dermal density, particularly for the periorbital and perioral regions.
Where the evidence is still thin: melasma (mixed results, some risk of post-treatment pigmentation flare), keloid and hypertrophic scarring (caution required), and routine "skin tightening" claims for which the marketing has run ahead of the data.
Microneedling in skin of colour: Fitzpatrick IV–VI
Microneedling is often positioned as a lower-risk option for patients with higher Fitzpatrick skin types compared to fractional laser, and that reputation is broadly accurate. The absence of photothermal energy removes one of the primary drivers of post-treatment hyperpigmentation in darker skin. However, the Cureus review and the accumulated clinical literature flag specific risks that practitioners treating Fitzpatrick IV–VI patients should manage actively.
Post-inflammatory hyperpigmentation remains a real risk in darker skin types, particularly with aggressive needle depth, high-frequency sessions, or where post-treatment care permits sun exposure before the skin has healed. Darker skin has a greater density of active melanocytes in the basal layer of the epidermis, and any dermal trauma that triggers melanocyte activation can produce PIH. The treatment is not risk-free in this population because it avoids laser energy. It carries a different risk profile that requires the same calibrated approach.
Protective strategies the literature supports:
- Pre-treatment with topical depigmenting agents (niacinamide, azelaic acid, tranexamic acid) for four to six weeks in patients with a PIH history or Fitzpatrick IV–VI, to lower baseline melanocyte activity before the first session.
- Conservative needle depth for initial sessions, with depth increases only after establishing how that individual skin type responds across a full healing cycle.
- Strict post-treatment sun protection, with SPF 50 broad-spectrum sunscreen and sun avoidance for the first seven days. This is both clinical care and a consent-documentation requirement.
- Extended intervals between sessions in higher Fitzpatrick types, to allow complete resolution of post-procedural erythema before the next treatment cycle.
The clinical and ethnic diversity of UK aesthetics practice makes this section non-optional. Practitioners offering microneedling who have not considered their approach to Fitzpatrick IV–VI patients have a gap in their consent process and their clinical framework alike.
Radiofrequency-assisted microneedling: a different modality
RF-assisted microneedling combines controlled dermal micro-injury with radiofrequency energy delivered through insulated needles. The RF component creates focal zones of thermal coagulation in the dermis at precisely set depths, while the needle channels provide the wound-healing stimulus of standard microneedling. The combined effect is more powerful than either alone for indications that require both collagen induction and tissue tightening.
The 2024 Cureus review identifies RF-assisted microneedling as the highest-complexity category of the technique, with stronger evidence for:
- Atrophic acne scarring: studies comparing RF microneedling against standard microneedling consistently report superior scar remodelling, with thermal energy accelerating collagen cross-linking and contraction.
- Skin laxity: the thermal component contracts existing collagen and stimulates neocollagenesis in the deeper dermis, which is the indication where RF microneedling most clearly outperforms the non-RF modality.
- Periorbital and lower-face rhytids: particularly in patients with early tissue laxity who are not yet surgical candidates.
The clinical decision between standard and RF-assisted microneedling turns on the indication, the required depth of effect, and the patient's Fitzpatrick skin type. RF-assisted devices are not inherently safer in darker skin tones. The thermal component can drive post-treatment hyperpigmentation in Fitzpatrick IV–VI if depth, temperature, and cooling parameters are not carefully managed. This runs counter to what some promotional materials imply.
From a regulatory standpoint, RF-assisted microneedling devices carry different classification obligations. Devices that deliver both needle-based dermal injury and RF energy are typically Class IIb or Class III under UK Medical Devices Regulations. The MHRA guidance on device classification applies to each device individually. Practitioners should confirm the CE marking status, notified body certificate, and instructions for use for any RF device in use and should retain that documentation in the practice file.
The treatment record for RF microneedling should reflect the increased technical complexity: device settings (needle depth, tip type, energy level, pass count) alongside the standard consent form, pre-treatment photographs, and post-session care instructions all belong in the file.
Safety profile and what the literature flags
The reviewed literature reports a generally favourable safety profile for standard microneedling. Common adverse events are erythema, transient pinpoint bleeding, and post-procedural sensitivity, typically resolving within days. Serious events are rare but include infection (particularly when sterility protocols slip), tram-track scarring with overly aggressive treatment, and post-inflammatory hyperpigmentation in higher Fitzpatrick skin types.
The British Association of Dermatologists' service standards sit alongside the evidence as the practical UK reference for the standards under which dermatologic procedures should be delivered. They are the right benchmark for any practitioner offering microneedling outside a hospital setting.
Infection control is the single most frequently cited preventable risk in the literature. Sterility of the treatment environment, single-use tips, and appropriate disinfection protocols matter regardless of device type. A protocol that would satisfy a CQC inspection is the correct level.
Needle depth selection is the second most common source of adverse events in published case reports. Treating at depths appropriate to the indication and the patient's anatomy, rather than defaulting to the device maximum, is the consistent message from the evidence.
UK regulatory position
Microneedling devices are typically CE/UKCA-marked as medical devices and fall under the MHRA. Clinical practice falls under your professional regulator and, where applicable, the national clinical regulator: CQC in England, with HIS, HIW and RQIA in the devolved nations.
Section 180 of the Health and Care Act 2022 gives the Secretary of State the power to introduce a national licensing scheme for non-surgical cosmetic procedures in England. No such scheme is in force. The secondary regulations, procedure lists and start date have not been made. The regulation overview maps what is live law now and what remains proposal. The JCCP position, and the direction of the 2025 government consultation response, is that deeper energy-based procedures including RF microneedling are likely to fall within scope when secondary legislation is finalised. Standard non-RF microneedling may sit in a lower tier depending on depth and device type.
What this means in practice: preparing documentation now to a standard that would satisfy an inspection under a future licensing scheme costs nothing and protects the practice under the existing professional and insurance standards. The JCCP accreditation and CPD records are both preparation and live compliance.
For practitioners who want a structured approach to staying current with both the clinical landscape and the regulatory environment, the RAG Pathway is the four-week programme that maps the territory: from the Health and Care Act through to JCCP standards, MHRA device regulation, and the evidence frameworks that underpin clinical decision-making. The free two-day introduction is open now.
FAQ
Is there NICE guidance specifically for microneedling?
No standalone NICE guideline addresses microneedling as a category. The British Association of Dermatologists produces the most relevant UK clinical reference points, with their guidelines accredited by NICE. The peer-reviewed dermatology literature provides the substantive evidence base for the specific indications.
What does the 2024 evidence say about microneedling for acne scars?
The recent systematic literature reports consistent efficacy for atrophic acne scarring, particularly icepick and rolling scars, with multiple RCTs showing statistically significant improvement. The strongest results emerge when microneedling is integrated with topical or procedural adjuncts, rather than used as monotherapy.
Is microneedling safe in higher Fitzpatrick skin types?
It can be, but the evidence flags an elevated risk of post-inflammatory hyperpigmentation in skin types IV–VI, particularly with aggressive depth or frequency. Practitioner experience with darker skin tones, conservative parameters, and pre-treatment with topical depigmenting agents are repeatedly cited in the literature as the appropriate protective strategy.
How does microneedling compare to fractional laser?
Both rely on controlled dermal injury to trigger collagen induction. Fractional laser typically achieves deeper effects with shorter recovery in skilled hands, but carries a higher risk of pigmentation complications in darker skin types. Microneedling is generally considered safer across the full Fitzpatrick range, with broader indications but a longer treatment course to reach equivalent outcomes for deeper scarring.
Is RF microneedling covered by the same evidence as standard microneedling?
Not entirely. The 2024 Cureus systematic review covers RF-assisted microneedling separately and finds stronger evidence for scar remodelling and skin laxity compared to standard microneedling. The safety considerations also differ: the thermal component adds a risk of hyperpigmentation in darker skin tones that standard microneedling does not carry to the same degree. Treat each modality on its own evidence base.
Will microneedling fall under the UK aesthetics licensing scheme?
No national aesthetics licensing scheme is in force in England as of 2026. Section 180 of the Health and Care Act 2022 enables the government to make future licensing regulations, but no secondary legislation or commencement date has been enacted. The risk-based framework in the 2025 consultation response suggests deeper microneedling, particularly RF-assisted devices, is likely to fall within scope when secondary legislation is finalised. The regulation overview tracks the live position.
Bernadette Tobin is a Registered Nurse and Independent Nurse Prescriber with an MSc in Advanced Practice (Level 7). She is the founder of Aesthetics Unlocked and a 2026 Educator of the Year Nominee at the Beauty and Aesthetics Awards. She runs Visage Aesthetics in Essex, named Best Non-Surgical Aesthetics Clinic 2026 by the Health, Beauty and Wellness Awards. Verifiable on the NMC public register.